Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

and Victoza), and 45% for the second-generation GLP-1 drugs (Mounjaro, Ozempic, Rybelsus, Wegovy, and Zepbound). All were ...

Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

This list can have an impact on your drug coverage in 2025 and shows why this open enrollment is so important.

In addition, the mean body weight was reduced by 17, 21 and 25 pounds, respectively, as compared to 13 pounds with Ozempic 1 mg ... approved in this class was Victoza. Later on, it also became ...

We do have negative adjustments on Victoza related to prior periods driven by higher exposure toward Medicaid in the U.S. And ...

We’re using it for fatty liver [disease], high cholesterol, you name it.” Ozempic, Mounjaro, Wegovy, Victoza and Trulicity ...

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...

ATLANTA — Popular drugs like Ozempic and Wegovy are known for dramatic weight loss, but they also can potentially help with ...